Avita Medical Surges on FDA Approval for Recell Go Mini

Dec 24, 2024

Avita Medical Limited (ASX: AVH) saw its shares climb 7.6% to $4.10 after receiving pre-market approval from the U.S. Food and Drug Administration (FDA) for its Recell Go mini product. This innovative device is specifically designed to treat smaller wounds, expanding the company’s offerings in the skin repair sector. The approval represents a significant milestone, positioning Avita Medical to address a broader range of wound care needs in the U.S. market.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com

GET A FREE STOCK REPORT

Download the latest small cap report for free now!!

By submitting your details and clicking on the button above, you agree to our Terms and Conditions, Privacy Policy and consent to receive marketing offers including to be contacted by email or phone. Before continuing, please read the Financial Services Guide available here.